Search Results
Found 2 results
510(k) Data Aggregation
(898 days)
Immuno Concepts N.A., Ltd.
The Immuno Concepts IgG Anti-nDNA Fluorescent Test System is for in vitro diagnostic use for the qualitative detection and semi-quantitation of anti-nDNA antibodies of the IgG class in human serum by manual fluorescent microscopy or with the Image Navigator® Fluorescence Semiautomated Microscope. The Immuno Concepts IgG Anti-IDNA Fluorescent Test System is to be used as an aid in the diagnosis of Systemic Lupus Erythematosus (SLE) in conjunction with other clinical and laboratory findings. A trained operator must confirm results generated with the Image Navigator® semi-automated device and software.
Not Found
The provided text is a 510(k) premarket notification clearance letter from the FDA for the "Immuno Concepts IgG Anti-nDNA Fluorescent Test System" and the "Image Navigator® Fluorescence Semiautomated Microscope." It details the device's indications for use and general regulatory information but does not contain the specific acceptance criteria, study details, or performance data that would allow for a complete answer to your request.
Therefore, I cannot extract the following information from the provided text:
- A table of acceptance criteria and the reported device performance
- Sample size used for the test set and the data provenance
- Number of experts used to establish the ground truth for the test set and the qualifications of those experts
- Adjudication method for the test set
- Whether a multi-reader multi-case (MRMC) comparative effectiveness study was done, or the effect size
- Whether a standalone (algorithm only) performance study was done
- The type of ground truth used (expert consensus, pathology, outcomes data, etc.)
- The sample size for the training set
- How the ground truth for the training set was established
The document primarily states that the FDA has determined the device is substantially equivalent to legally marketed predicate devices. To find the detailed study information, one would typically need to review the full 510(k) summary or the pivotal study report submitted by the manufacturer to the FDA, which is not included in this clearance letter.
Ask a specific question about this device
(62 days)
IMMUNO CONCEPTS, N.A., LTD
These are qualitative calibrators/controls to confirm the presence of antibodies to autoantigens (Jo-1, Scl-70, or PCNA) in human serum. Antibodies to Jo-1 are found in patients with polymyositis and dermatomyositis, antibodies to Scl-70 are found in patients with scleroderma, and antibodies to PCNA are found in patients with systemic lupus erythematosus. These optional controls are intended for use with the Immuno Concepts AUTO-ID® Autoantibody Test System.
AUTO-I.D.® Jo-1 Positive Control Serum (Catalog number 6004) AUTO-I.D.® Sc1-70 Positive Control Serum (Catalog number 6005) AUTO-I.D.® PCNA Positive Control Serum (Catalog number 6006)
This document is a 510(k) premarket notification approval letter for the Immuno Concepts Incorporated's Auto I.D.® Jo-1, Scl-70, and PCNA Positive Controls. It indicates the products are substantially equivalent to legally marketed predicate devices. This type of document does not contain details about specific acceptance criteria or an in-depth study proving device performance against those criteria.
The purpose of a 510(k) submission is to demonstrate substantial equivalence, not necessarily to provide detailed performance studies in the way you might find for a novel, high-risk device. The approval letter confirms the device can be legally marketed, but it doesn't typically elaborate on the specific performance study results that were part of the submission package.
Therefore, I cannot provide the requested information because the provided text does not contain it. The text focuses on the regulatory approval, indicating the device is a "qualitative calibrator/control to confirm the presence of antibodies to autoantigens." This implies performance validation related to its role as a control, likely confirming the presence of the respective antibodies, but the details of such validation are not in this approval letter.
Ask a specific question about this device
Page 1 of 1